Acorda Therapeutics

Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its products include Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), Fampyra (fampridine) and Selincro (nalmefene). The firm's also offers Research and Development Programs like ARCUS for acute migraine, Cimaglermin alfa and rHIgM22. The company was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Global Ecology Corp. engages in the development, production and marketing of advanced waste remediation technologies that address universal environmental issues, which include organic soil revitalization, reduction of greenhouse gas emissions, solid waste remediation and point-of-use water purification solutions. The company was founded in 1993 and is headquartered in Las Vegas, NV.

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in Cash.

Acorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in Cash

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China.

Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda First Quarter 2023 Update: Webcast/Conference Call Scheduled for May 11, 2023.

Acorda First Quarter 2023 Update: Webcast/Conference Call Scheduled for May 11, 2023

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Present INBRIJA® Data at the American Academy of Neurology Annual Meeting.

Acorda Therapeutics to Present INBRIJA® Data at the American Academy of Neurology Annual Meeting

Acorda Therapeutics, Inc. (NASDAQ:ACOR ) Q4 2022 Earnings Conference Call March 9, 2023 8:30 AM ET Company Participants Tierney Saccavino - Investor Relations Ron Cohen - President and Chief Executive Officer Michael Gesser - Chief Financial Officer Conference Call Participants Boobalan Pachaiyappan - H.C. Wainwright Operator Welcome to the Acorda Therapeutics Fourth Quarter and Year-End 2022 Financial and Business Update.

Acorda Therapeutics, Inc. (ACOR) Q4 2022 Earnings Call Transcript

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today reported its financial results for the fourth quarter and full year ended December 31, 2022.

Acorda Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Acorda Fourth Quarter/Year End 2022 Update: Webcast/Conference Call Scheduled for March 9, 2023

Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement

PEARL RIVER, N.Y.--( BUSINESS WIRE )--Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acorda's President and Chief Executive Officer, will make a virtual presentation at the Sequire Biotechnology Conference on Thursday, February 2 at 3:00 p.m. ET.

Acorda Therapeutics to Present at Sequire Biotechnology Conference

PEARL RIVER, N.Y.--( BUSINESS WIRE )--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that on December 31, 2022 it entered into a new long-term global supply agreement with Catalent for the manufacture of INBRIJA (levodopa inhalation powder) at its Center of Excellence for Spray Dried Dispersions in Boston where Catalent will continue to manufacture INBRIJA through 2030. The new agreement includes the scale-up to the larger pharma grade spray-dryer at a PSD-7 scale, which will provide expanded capacity for the long-term world-wide manufacturing requirements of INBRIJA.

Acorda Therapeutics Announces New Agreement with Catalent for Long-Term Global Supply of INBRIJA®

Macy's

PEARL RIVER, N.Y.--( BUSINESS WIRE )--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has revised and updated the long-term financial guidance most recently included in its November 1, 2022 press release announcing its financial results for the third quarter of 2022. The revised guidance corrects certain errors identified in the Company's year-end budgeting process that overstated the Company's projected Adjusted EBITDA and ending cash balances for 2022-2027.

Acorda Therapeutics Announces Revised Long-Term Financial Guidance

PEARL RIVER, N.Y.--( BUSINESS WIRE )--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it was notified by the Listing Qualifications Staff of The Nasdaq Stock Market LLC that, due to the Company's common stock not having regained compliance with the minimum price of $1.00, the stock is subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel. The Company plans to submit such request within the required seven calendar days, which will stay any suspension or delisting action pending the hearing and the expiration of any additional extension period granted by the Hearings Panel following the hearing. The Hearings Panel has the discretion to grant the Company an extension through June 17, 2023.

Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request a Hearing

PEARL RIVER, N.Y.--( BUSINESS WIRE )--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it made a cash interest payment of approximately $6.2 million due on December 1, 2022 under its Convertible Senior Secured Notes Indenture.

Acorda Therapeutics Makes December 2022 $6.2 Million Interest Payment on Secured Debt in Cash

PEARL RIVER, N.Y.--( BUSINESS WIRE )--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the Company's stockholders approved the Reverse Stock Split proposal at its reconvened Special Meeting of Stockholders.

Acorda Therapeutics Announces Passage of Reverse Stock Split Proposal at its Special Meeting of Stockholders

Acorda Therapeutics, Inc. (Nasdaq: ACOR) convened its Special Meeting of Stockholders on November 4, 2022, and a proposal to adjourn the meeting was approved in order to provide stockholders with additional time to vote on Proposal Two, Reverse Stock Split. The Special Meeting will be reconvened on November 11, 2022 at 9:00 a.m. Eastern Time at the Company's offices located at Two Blue Hill Plaza, 3rd Floor, Pearl River, New York 10965. The sole matter of business before the reconvened Special Meeting will be to approve Proposal Two, the Reverse Stock Split.

Acorda Therapeutics Announces Adjournment of Special Meeting of Stockholders

Acorda Therapeutics, Inc. (NASDAQ:ACOR ) Q3 2022 Results Conference Call November 1, 2022 4:30 PM ET Company Participants Tierney Saccavino - Investor Relations Ron Cohen - President and Chief Executive Officer Michael Gesser - Chief Financial Officer Conference Call Participants Raghuram Selvaraju - H.C. Wainwright Operator Welcome to Acorda Therapeutics' Third Quarter 2022 Financial and Business Update.

Acorda Therapeutics, Inc. (ACOR) Q3 2022 Earnings Call Transcript

Acorda Therapeutics Reports Third Quarter 2022 Financial Results

Acorda Therapeutics Inc (NASDAQ:ACOR) has provided long-term financial guidance and an updated business plan in preparation for the special meeting of its stockholders this week, and updated its net revenue forecast from US$116 million to $121 million in 2023, and as much as $199 million by 2027. The Pearl River, New York-based company said it expects to increase the market for two of its pharmaceuticals – Inbrija for patients with Parkinson's disease, and Ampyra, used to treat adults with multiple sclerosis.

Acorda Therapeutics supplies long-term guidance and business plan in preparation for shareholders meeting

Acorda Therapeutics Provides Long-Term Business Plan and Financial Guidance

Acorda Third Quarter 2022 Update: Webcast/Conference Call Scheduled for November 1, 2022

Atossa Genetics

Atara Biotherapeutics

PAVmed

Xeris Biopharma Holdings

Biotech penny stocks for your watch list this week. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 5 Biotech Stocks For Your Watch List This Week

Acorda Shareholders Invited to Virtual Q&A with CEO Ron Cohen, M.D.

ISS, Glass Lewis, and Egan-Jones Recommend that Acorda Stockholders Vote FOR the Proposal to Implement a Reverse Stock Split

Acorda Therapeutics Will Not Use Shares for December 2022 $6.2 Million Interest Payment on Secured Debt

American Virtual Cloud Technologies

Federated National Hld

Nutex Health Inc

Use these tricks for finding penny stocks to buy this week The post How to Find Penny Stocks to Buy Right Now  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

News for Acorda Therapeutics Stock (ACOR)